Quetiapine‐induced sleep‐related eating disorder: A case report

Kanagasundram, Sharmilla

doi:10.1002/ccr3.4168

Cited by 4 publications

(8 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In both cases, SRED behaviors were remitted after the quetiapine’s discontinuation and CPAP therapy. Quetiapine was associated with new-onset SRED in a case series (N=2 patients) when administered in doses of 50–200 mg/day ( 43 ).…”

Section: Resultsmentioning

confidence: 99%

“…Although the Z-drugs (zolpidem, zaleplon, zopiclone, eszopiclone) target more specifically a-1 subunits of the GABA-A receptors due to their chemical structure (they are imidazopyridines), unlike benzodiazepines or barbiturates, these agents share common pharmacological effects with other GABA-A receptor agonists, the risk of abuse and physiological dependence being included (111,112). Zolpidem, several second and thirdgeneration antipsychotic agents (e.g., olanzapine, quetiapine), and antidepressants (e.g., serotonin selective reuptake inhibitors-SSRIs, bupropion) have been associated with sleepwalking or SRED (42)(43)(44). Hypnosedative drugs have been associated with various complex sleep behaviors, such as sleep-driving, sleep cooking, SRED, sleep talking, sexsomnia, etc.…”

Section: The Drug-induced Sredmentioning

confidence: 99%

See 1 more Smart Citation

Current evidence and future perspectives in the exploration of sleep-related eating disorder–a systematic literature review

Vasiliu

2024

Front. Psychiatry

View full text Add to dashboard Cite

Sleep-related eating disorder (SRED) is a non-REM parasomnia with potentially significant negative effects on general health (dangerous activities during night eating episodes, obesity, or metabolic syndrome, for example). Although the history of SRED encompasses more than six decades, public awareness and even the awareness of the mental health specialists of this disorder is very limited, a phenomenon that hinders the development of research in this field. Therefore, a systematic review based on PRISMA 2020 guidelines explored the available evidence for SRED found in four electronic databases (PubMed, Cochrane Collaboration, Google Scholar, and Clarivate/Web of Science). A number of 94 primary and secondary reports were retrieved, investigating aspects regarding the risk factors, epidemiology, clinical data and differential diagnosis, epidemiology, structured evaluation, and treatment of SRED. Based on the results of these reports, Z-drugs, but also certain benzodiazepines, antidepressants, antipsychotics, and psychostimulants may trigger the onset of SRED. Psychiatric and neurologic disorders have also been associated with SRED, either as risk factors or comorbid conditions. Cerebral glucose metabolism dysfunctions, neurotransmitter dysfunctions, and genetic factors have been invoked as pathogenetic contributors. Structured assessment of SRED is possible, but there is a dearth of instruments dedicated to this purpose. Data on the prevalence and treatment of SRED exist, but good-quality epidemiological studies and clinical trials are still missing. In conclusion, future research is expected to address the shortcomings of SRED exploration by creating the conditions for better quality and larger group clinical research. The need for such investigation is granted by the importance of this pathology and its negative functional consequences.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: The Drug-induced Sredmentioning

confidence: 99%

Current evidence and future perspectives in the exploration of sleep-related eating disorder–a systematic literature review

Vasiliu

2024

Front. Psychiatry

View full text Add to dashboard Cite

show abstract

“…In fact, AAPs might increase the degree of hunger, while lowering the satiating efficiency [7]. Further, patients treated with AAPs may show tendencies for recurrent episodes of dietary disinhibition, which may favor proper eating disorders [8]. Indeed, the involvement of serotonin and histamine in the control of appetite is well known, and H1 receptor blockade showed the strongest association with body weight gain [9].…”

Section: Discussionmentioning

confidence: 99%

“…By contrast, promoters of SRED include sleepwalking, restless legs syndrome, obstructive sleep apnea, various causes of sleep fragmentation, delayed circadian rhythm of eating, daytime eating disorders, and increased central dopamine release [4,[6][7][8][9].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Medications as a Trigger of Sleep-Related Eating Disorder: A Disproportionality Analysis

Merino

Gérard

Obberghen

et al. 2022

JCM

View full text Add to dashboard Cite

Sleep-related eating disorder (SRED) is a parasomnia with recurrent, involuntary, amnestic eating episodes during sleep. There is growing evidence of the association between SRED and medications. Therefore, we aimed to rank drugs showing the strongest association. VigiBase® (WHO pharmacovigilance database) was queried for all reports of “Sleep-related eating disorder”. Disproportionality analysis relied on the Reporting Odds Ratio, with its 95% Confidence Interval (CI), and the Information Component. Our VigiBase® query yielded 676 cases of drug-associated SRED. Reports mostly involved zolpidem (243, 35.9%), sodium oxybate (185, 27.4%), and quetiapine (97, 14.3%). Significant disproportionality was found for 35 medications, including zolpidem (387.6; 95%CI 331.2–453.7), sodium oxybate (204.2; 95%CI 172.4–241.8), suvorexant (67.3; 95%CI 38.0–119.2), quetiapine (53.3; 95%CI 43.0–66.1), and several psychostimulants and serotonin-norepinephrine reuptake inhibitors (SNRIs). Patients treated with nonbenzodiazepines or SNRIs were significantly older (mean age: 49.0 vs. 37.5; p < 0.001) and their SRED were more likely to be serious (62.6% vs. 51.4%; p = 0.014) than patients treated with sodium oxybate or psychostimulants. Psychotropic drugs are involved in almost all reports. In patients with SRED, an iatrogenic trigger should be searched for.

show abstract

Current Evidence and Future Perspective in the Exploration of Sleep-Related Eating Disorder—From Pathogenic Hypotheses to Treatment Approaches

Vasiliu

2023

Preprint

View full text Add to dashboard Cite

Sleep-related eating disorder (SRED) is a non-REM parasomnia with potentially significant negative effects on general health (dangerous activities during night eating episodes, obesity, or metabolic syndrome, for example). Although the history of SRED encompasses more than six decades, public awareness and even the awareness of the mental health specialists of this disorder is very limited, a phenomenon that hinders the development of research in this field. Therefore, an updated review, based on a narrative methodology, explored the available evidence for SRED found in four electronic databases (PubMed, Cochrane Collaboration, Google Scholar, and Clarivate/Web of Science). A number of 94 primary and secondary reports were retrieved, investigating aspects regarding the risk factors, epidemiology, clinical data and differential diagnosis, epidemiology, structured evaluation, and treatment of SRED. Based on the results of these reports, Z-drugs, but also certain benzodiazepines, antidepressants, antipsychotics, and psychostimulants may trigger the onset of SRED. Psychiatric and neurologic disorders have also been associated with SRED, either as risk factors or comorbid conditions. Cerebral glucose metabolism dysfunctions, neurotransmitter dysfunctions, and genetic factors have been invoked as pathogenetic contributors. Structured assessment of SRED is possible, but there is a dearth of instruments dedicated to this purpose. Data on the prevalence and treatment of SRED exist, but good-quality epidemiological studies and clinical trials are still missing. In conclusion, future research is expected to address the shortcomings of SRED exploration by creating the conditions for better quality and larger group clinical research. The need for such investigation is granted by the importance of this pathology and its negative functional consequences.

show abstract

Quetiapine‐induced sleep‐related eating disorder: A case report

Cited by 4 publications

References 20 publications

Current evidence and future perspectives in the exploration of sleep-related eating disorder–a systematic literature review

Current evidence and future perspectives in the exploration of sleep-related eating disorder–a systematic literature review

Medications as a Trigger of Sleep-Related Eating Disorder: A Disproportionality Analysis

Current Evidence and Future Perspective in the Exploration of Sleep-Related Eating Disorder—From Pathogenic Hypotheses to Treatment Approaches

Contact Info

Product

Resources

About